Entropy Neurodynamics Completes Dosing of First Patient in Binge Eating Disorder Trial
MT Newswires Live
Dec 16, 2025
Entropy Neurodynamics (ASX:ENP) completed dosing of the first patient with the second infusion of its TRP-8803 drug candidate, or intravenous-infused psilocin, in its binge eating disorder trial being conducted alongside Swinburne University, according to a Tuesday Australian bourse filing.
The planned clinical trial, which aims to recruit a total of 12 patients suffering from binge eating disorder, in two six-person groups, the company said. Each group will be given two doses of TRP-8803 14 days apart, along with supportive psychotherapy.
The patient will undergo supportive psychotherapy, ahead of post-treatment review in four weeks, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.